Massimo Bertinaria

List of Publications by Citations

36 papers	787 citations	17 h-index	27 g-index
45 ext. papers	885 ext. citations	5.5 avg, IF	3.24 L-index

#	Paper	IF	Citations
36	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. *Journal of Medicinal Chemistry*, **2017**, 60, 3656-3671	8.3	95
35	Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 5271251	6.7	61
34	Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. *Journal of Medicinal Chemistry*, **2014**, 57, 10366-82	8.3	58
33	Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors. *ChemMedChem*, **2016**, 11, 1790-803	3.7	46
32	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *Journal of Medicinal Chemistry*, **2006**, 49, 2886-97	8.3	43
31	Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7900-7	3.4	37
30	Synthesis and antimalarial activities of some furoxan sulfones and related furazans. *European Journal of Medicinal Chemistry*, **2005**, 40, 1335-40	6.8	32
29	Edaravone derivatives containing NO-donor functions. *Journal of Medicinal Chemistry*, **2009**, 52, 574-8	8.3	31
28	Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents. *Journal of Medicinal Chemistry*, **2011**, 54, 611-21	8.3	27
27	A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. *European Journal of Medicinal Chemistry*, **2009**, 44, 5071-9	6.8	27
26	Synthesis and anti-Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. *Drug Development Research*, **2003**, 60, 225-239	5.1	27
25	Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. *European Journal of Medicinal Chemistry*, **2011**, 46, 1757-67	6.8	26
24	Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans. *Journal of the Chemical Society, Perkin Transactions 1*, **2001**, 1751-1757		23
23	Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors. *ChemMedChem*, **2012**, 7, 1647-60	3.7	22
22	Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans. *Journal of Medicinal Chemistry*, **2007**, 50, 5003-11	8.3	22
21	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. *Frontiers in Pharmacology*, **2018**, 9, 1405	5.6	22
20	[3-(1H-imidazol-4-yl)propyl]guanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 1197-205	3.4	21

19	Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. *Archives of Biochemistry and Biophysics*, **2019**, 670, 116-139	4.1	17
18	NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria. *Journal of Medicinal Chemistry*, **2015**, 58, 7895-9	8.3	15
17	Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4750-9	3.4	13
16	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 2107-16	3.4	12
15	Synthesis and Pharmacological Characterization of New H2-Antagonists Containing NO-Donor Moieties, Endowed with Mixed Antisecretory and Gastroprotective Activities. *Helvetica Chimica Acta*, **2000**, 83, 287-299	2	12
14	A new class of NO-donor H3-antagonists. *Il Farmaco*, **2004**, 59, 359-71		11
13	Anti-Helicobacter pylori agents endowed with H2-antagonist properties. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 403-6	2.9	11
12	Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile. *European Journal of Medicinal Chemistry*, **2012**, 54, 103-12	6.8	10
11	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 9219825	6.7	10
10	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. *Pharmacological Research*, **2016**, 103, 132-43	10.2	9
9	Antisecretory and gastroprotective activities of compounds endowed with H2 antagonistic and nitric oxide (NO) donor properties. *Journal of Physiology (Paris)*, **2000**, 94, 5-10		9
8	Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isotere. *Journal of Electroanalytical Chemistry*, **2004**, 571, 177-182	4.1	8
7	A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives. *Journal of Biomolecular Screening*, **2013**, 18, 211-8		6
6	Non-imidazole histamine NO-donor H3-antagonists. *Il Farmaco*, **2005**, 60, 507-12		5
5	Structure-antioxidant activity relationships in a series of NO-donor phenols. *ChemMedChem*, **2008**, 3, 1443-8	3.7	4
4	H3 receptor ligands: new imidazole H3-antagonists endowed with NO-donor properties. *Il Farmaco*, **2003**, 58, 279-83		4
3	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. *Gastroenterology*, **2016**, 150, S968-S969	13.3	3
2	Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. *Molecules*, **2021**, 26,	4.8	3

1 Amphiphilic NO-donor antioxidants. *ChemMedChem*, **2007**, 2, 234-40 3.7 2